This is the authors' abstract. We don't add key points for this paper.
The first structural determination of dinuclear compounds with μ1,5‐dicyanamide [dca, N(CN)2−] as bridging ligand has been achieved with the products of formula [Ni(µ1,5‐dca)(dca)(dpt)]2 (1) and [Ni(µ1,5‐dca)(dca)(medpt)]2 (2) [dpt = bis(3‐aminopropyl)amine and medpt = bis(3‐aminopropyl)methylamine]. The X‐ray diffraction analysis reveals dinuclear compounds with double μ1,5‐dicyanamide bridges. The nickel atoms are hexacoordinate. The small differences in the terminal ligand (dpt or medpt) create a drastic change in the magnetic behaviour: the susceptibility measurements of 1 show weak antiferromagnetic coupling (J = −1.2 cm−1, g = 2.29) whereas those of 2 show ferromagnetic coupling (J = 0.7 cm−1, g = 2.17). The related compound (μ‐terephthalato)[Ni(dca)(dpt)(H2O)]2 (3) is also described. The X‐ray diffraction analysis reveals a dinuclear terephthalato‐bridged NiII compound with terminal dca ligands. The susceptibility measurements of 3 indicate weak antiferromagnetic coupling: J = −0.3 cm−1, g = 2.13. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ghoshal et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: